Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022
Tebentafusp Granted Rare EU Accelerated Assessment
The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The European Medicines Agency has added seven new products to its list of medicines that are under review for potential EU marketing authorization.
After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?